Criteria for Male Bone Density Screening
Men should undergo DXA bone density screening at age 70 years or older, or at any age if they have major risk factors including previous fragility fracture, prolonged corticosteroid use, androgen deprivation therapy, or conditions/medications affecting bone metabolism 1, 2.
Age-Based Screening
- Men ≥70 years: Universal screening recommended 1, 2
- Men 50-69 years: Screen only if risk factors present 1
Major Risk Factors Warranting DXA at Any Age
The following high-risk conditions justify immediate screening regardless of age:
- Previous fragility fracture (low-trauma fracture after age 50) 1, 2
- Prolonged corticosteroid use (particularly high-dose or long-term therapy) 3, 1
- Androgen deprivation therapy (for prostate cancer treatment) 1
- Diseases affecting bone metabolism:
- Rheumatoid arthritis 3
- Chronic kidney disease
- Liver disease
- Malabsorption syndromes
- Hyperparathyroidism
- Hyperthyroidism
Additional Risk Factors
When present, these factors lower the threshold for screening in men under 70:
- Low body weight (BMI <20-25 kg/m²) 1
- Significant weight loss (>10% body weight) 1
- Physical inactivity/immobilization 1
- Family history of osteoporotic fracture (especially parental hip fracture) 4
- Excessive alcohol consumption 1
- Current smoking 4
Clinical Context
Men are substantially underscreened compared to women, accounting for only 10% of DXA tests despite representing 24% of hip fractures 4. The 1-year mortality after hip fracture is twice as high in men compared to women 1, making identification of at-risk men particularly important.
Common Pitfalls
- Don't wait for a fracture: Only 19% of men over 65 receive screening after a fracture 4, representing a major missed opportunity
- Don't assume osteoporosis is a "women's disease": Men have a 25% lifetime risk of osteoporotic fracture after age 60 1
- Screen men with rheumatoid arthritis aggressively: This population has particularly high risk 3
Monitoring Considerations
For men already on treatment or with established low bone mass:
- Repeat DXA is indicated to monitor treatment response 2
- Post-fracture screening is cost-effective and should be routine 3
- Men on glucocorticoids require both baseline and follow-up screening 3
The evidence strongly supports that screening in high-risk men is cost-effective, particularly in those with prior fractures, on corticosteroids, or with rheumatoid arthritis 3. Universal screening becomes cost-effective at age 80 and older 1.